• Saved

Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target

Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target

Source : https://www.nature.com/articles/s41588-020-00758-y

Half of all colorectal cancers bear KRAS-activating mutations that affect the metabolic dependencies of cancer cells and drive resistance to commonly used drugs. A new study provides insights into KRAS-driven metabolic rewiring and identifies a new therapeutic target for KRAS-mutant cancers.